Morgan Stanley vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Morgan Stanley | Pfizer Inc. |
|---|---|---|
| Revenue | $70.6B | $62.6B |
| Founded | 1935 | 1849 |
| Employees | 83,000 | 75,000 |
| Market Cap | $340.2B | $148.0B |
| Headquarters | United States | United States |
Quick Stats Comparison
| Metric | Morgan Stanley | Pfizer Inc. |
|---|---|---|
| Revenue | $70.6B | $62.6B |
| Founded | 1935 | 1849 |
| Headquarters | New York, New York, United States | New York, New York |
| Market Cap | $340.2B | $148.0B |
| Employees | 83,000 | 75,000 |
Morgan Stanley Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Morgan Stanley | Pfizer Inc. | Leader |
|---|---|---|---|
| 2025 | $70.6B | $62.6B | Morgan Stanley |
| 2024 | $61.8B | $63.6B | Pfizer Inc. |
| 2023 | $54.1B | $59.6B | Pfizer Inc. |
| 2022 | N/A | $101.2B | Pfizer Inc. |
| 2021 | N/A | $81.3B | Pfizer Inc. |
Business Model Breakdown
Overview: Morgan Stanley vs Pfizer Inc.
This in-depth comparison examines Morgan Stanley and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Morgan Stanley on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Morgan Stanley and Pfizer Inc. is widest.
On the headline numbers, Morgan Stanley reports annual revenue of $70.6B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $340.2B and $148.0B. Morgan Stanley is headquartered in United States and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.
Morgan Stanley: Morgan Stanley's biggest strategic shift is that the firm has made wealth management a ballast against volatile capital markets. That does not eliminate cyclicality, but it changes the earnings mix from pure Wall Street deal flow toward a broader client-asset platform.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Business Models: How Morgan Stanley and Pfizer Inc. Make Money
Morgan Stanley and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Morgan Stanley and Pfizer Inc..
Morgan Stanley business model: Morgan Stanley operates through Institutional Securities, Wealth Management, and Investment Management. Revenue comes from advisory fees, underwriting, trading, commissions, asset-based fees, net interest income, lending, brokerage, investment products, and asset management fees.
Pfizer Inc. business model: Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.
Competitive Advantage: Morgan Stanley vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Morgan Stanley stack up against those of Pfizer Inc..
Morgan Stanley competitive advantage: The firm combines a top-tier institutional franchise with a scaled wealth platform. That mix gives Morgan Stanley access to corporate clients, ultra-high-net-worth households, workplace stock-plan participants, self-directed traders, and institutional investors.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
Growth Strategy: Where Morgan Stanley and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Morgan Stanley and Pfizer Inc. each plan to expand from here.
Morgan Stanley growth strategy: Morgan Stanley's growth strategy emphasizes wealth and investment management scale, workplace and self-directed client acquisition, institutional cross-selling, international client growth, lending to wealth clients, capital-light fee revenue, and disciplined capital returns.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
Financial Picture: Morgan Stanley vs Pfizer Inc.
A closer look at the financial trajectory of Morgan Stanley and Pfizer Inc. rounds out the comparison.
Morgan Stanley: For 2025, Morgan Stanley reported $70.645B in net revenues, $16.861B in net income, $10.21 diluted EPS, 21.6% ROTCE, and $1.420T in total assets. The year showed strong operating leverage as investment banking, trading, wealth management, and investment management all benefited from a healthier market backdrop.
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Company-Specific SWOT Notes
Morgan Stanley
The firm combines a top-tier institutional franchise with a scaled wealth platform.
Morgan Stanley wins by connecting institutional capital markets expertise with a massive wealth and investment management distribution platform.
The biggest risk is a sustained downturn in markets, dealmaking, or client activity that pressures both institutional revenue and wealth-management economics.
Morgan Stanley's growth strategy emphasizes wealth and investment management scale, workplace and self-directed client acquisition, institutional cross-selling, international client growth, lending to wealth clients, capital-light fee revenue, and disciplined capital returns.
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Morgan Stanley | Morgan Stanley reports the larger revenue base ($70.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1935 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Tied | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Morgan Stanley | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Morgan Stanley | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Morgan Stanley reports the larger revenue base ($70.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1935 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Morgan Stanley or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Morgan Stanley vs Pfizer Inc.
Is Morgan Stanley better than Pfizer Inc.?
Verdict: Between Morgan Stanley and Pfizer Inc., Morgan Stanley is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Morgan Stanley comes out ahead in this Morgan Stanley vs Pfizer Inc. comparison.
Who earns more — Morgan Stanley or Pfizer Inc.?
Morgan Stanley earns more with $70.6B in annual revenue versus Pfizer Inc.'s $62.6B. Morgan Stanley leads on total revenue based on latest verified figures.
Which company has higher revenue — Morgan Stanley or Pfizer Inc.?
Morgan Stanley reported $70.6B, while Pfizer Inc. reported $62.6B. The revenue leader is Morgan Stanley based on latest verified figures.
Morgan Stanley revenue vs Pfizer Inc. revenue — which is higher?
Morgan Stanley revenue: $70.6B. Pfizer Inc. revenue: $62.6B. Morgan Stanley has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Morgan Stanley Annual Filings (10-K, 8-K)
- Morgan Stanley Corporate Website
- Morgan Stanley Annual Report 2025 - Revenue and Financial Data
- sec.gov
- morganstanley.com
- morganstanley.com
- data.sec.gov
- morganstanley.com
- ourhistory.morganstanley.com
- stockanalysis.com
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com